Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001203199 | SCV001374351 | benign | Norman-Roberts syndrome; Familial temporal lobe epilepsy 7 | 2022-12-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004033564 | SCV004937389 | uncertain significance | Inborn genetic diseases | 2023-09-22 | criteria provided, single submitter | clinical testing | The c.1690C>A (p.L564I) alteration is located in exon 14 (coding exon 14) of the RELN gene. This alteration results from a C to A substitution at nucleotide position 1690, causing the leucine (L) at amino acid position 564 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |